Professional Documents
Culture Documents
October 2016 Let's Talk Informatics Presentation by Allscripts Vice-President Robert Leviton
October 2016 Let's Talk Informatics Presentation by Allscripts Vice-President Robert Leviton
Trends
Industry Challenges
Note: Data excludes the uninsured and VA populations, year = 2012. | Source: Oliver Wyman analysis, Kaiser, CMS, Census Bureau, CDC.
ELECTRONIC FINANCIAL
HEALTH RECORDS MANAGEMENT
PATIENTS
USE PORTAL
180K
Building Open, PHYSICIANS
2,500
Connected Communities HOSPITALS 19K
POST-ACUTE
FACILITIES
of Health™
CareInMotion Differentiators
Population Health
Management
• Aggregates community data to create a
True Harmonized View of the patient
CARE
ANALYTICS COORDINATION
• Puts care plans and interventions Into Action
Surveillance
Early
Warning
System
• End of Life
• Not Septic Shock,
Severe Sepsis
• Patient / Care Giver
Refuses Protocol
• Launch Sepsis Protocol
• Auto-Selects
Options
• Single Select
Launches
succeeding
order sets
• Preselected items
• Physician
Intelligence
• Quality Performance
• Infectious Disease
• Pharmacy
• Critical Care
• Drives Evidence
Based Care,
Outcomes, Cost
• Immediately
accessible
information
• Drives care
initiatives
• Focus on
outcome
• Link to cost and
decision making
Copyright © 2016 Allscripts Healthcare Solutions, Inc. 29
Clinical Summary- Discrete Data Single View
Single Summary View compiles days of admission data in one discrete location
– provides immediate review of pertinent information….and is configurable.
CARE
PHARMACY CLINICAL MOBILITY AND
ANALYTICS COORDINATION
OMICS WEARABLES
Allscripts Community Architecture
SPECIALIST
HOSPITAL &
HEALTH SYSTEMS
POST ACUTE
INTELLIGENT
INTERVENTION
PHYSICIAN
PRACTICE CONNECTIVITY & RESEARCH
PATIENT
DATA AGGREGATION ENGAGEMENT
Precision Medicine
Precision Medicine - Moving The Needle
Proactive Preventive
Reactive Predictive
Same diagnosis,
same drug
Diabetes Maturity Onset Diabetes of the Young (MODY) 1 of 50 from all diabetes cases
Neurodevelopmental
Neurodevelopmental monogenic disorders 1 of 30
disorders
Clinical Subset
Data Genomics Data Insights Cloud
Repository Repository Rules Genomics
Tenants
(CDR) Rules Ontology
(GDR) Orgs Rules dictionary
Users
AHS
Cerner EPIC dbMotion HIE FMH Genetic lab
EHRs
adapter adapter adapter adapter adapter adapter
adapter
States, Genetic
HIEs Labs 3rd party apps
3rd party Precision Medicine web app
applications 60
Copyright © 2016 Allscripts Healthcare Solutions, Inc.
Familial Hypercholesterolemia (FH)
• More than 80M adults have high cholesterol in the
US
• This double the risk for heart disease
• ~ 25% of adults over 40 are taking drugs to lower
their LDL (e.g., statin)
• Only a third of them will get it under control
• 1:500 (1:50 in early CVD ) have FH (~2 Million)
• 20x risk for CHD, 50% chance of a coronary
event before 50
• Only 50k of them are diagnosed correctly
• FH mutations (LDLR, APO-B, PCSK9)
• More likely to be resistant to common therapy
Copyright © 2016 Allscripts Healthcare Solutions, Inc. 61
Premature CHD in
High LDL in family family 1st degree PCSK9
1st degree APO-B New
member Pathogenic
member
mutation Premature CHD in
LDLR family 1st degree
tendon xanthoma member
and\or comeal
arcus in family 1st Genes
degree member personal &
environmental LDL = 320
Hypercholesterole factors Gene Mutations
mia mutations in
family member
age
Influence on risk
New
gender Knowledge pathogenic
mutation
ethnicity
Sources
LDL Tests for
Hypercholesterolemia Variates of
Blood Lab tests Tests for LDLR unknown
significance
TC Identified
Related conditions
Variations
First line therapy
May treat
Conditions
Medications
Biological
medications
Genetic
Other lipid-
Laboratory
Statins Early onset Early onset tendon xanthoma
lowering therapies CVD CHD and\or comeal arcus
Copyright © 2016 Allscripts Healthcare Solutions, Inc. 62
Familial Hypercholesterolemia (FH)
Doubled risk for cardiovascular disease (CVD)
• High cholesterol detected
Precision Medicine
• Life style changes
• Low dose statins • Identify individuals
• High dose statins • Genetic tests (and Life style Change)
• High potent statins Side effects • Clini-Omics prediction
• Second drug (Fibrate • Propose new class of drugs
etc….)
• New drugs (expensive)